Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-04 00:12 | 2025-10-02 | ALNY | Alnylam Pharmaceuticals Inc. | Garg Pushkal | Officer | SELL | $451.76 | 5,959 | $2,692,062 | 20,221 |
| 2025-10-04 00:24 | 2025-10-01 | CORT | CORCEPT THERAPEUTICS INC | BELANOFF JOSEPH K | Director, Officer | SELL | $85.08 | 40,000 | $3,403,252 | 2,781,370 |
| 2025-10-04 00:17 | 2025-10-01 | CORT | CORCEPT THERAPEUTICS INC | Lyon Joseph Douglas | Officer | OPT+S | $84.75 | 5,000 | $423,766 | 10,277 |
| 2025-10-04 00:15 | 2025-10-01 | CORT | CORCEPT THERAPEUTICS INC | Maduck Sean | Officer | OPT+S | $85.06 | 20,000 | $1,701,232 | 7,904 |
| 2025-10-03 20:18 | 2025-10-02 | SNGX | SOLIGENIX, INC. | SCHABER CHRISTOPHER J | Director, Officer | BUY | $1.32 | 15,132 | $20,000 | 15,511 |
| 2025-10-04 04:58 | 2025-10-02 | ELTP | ELITE PHARMACEUTICALS INC /NV/ | Plassche Douglas | Officer | SELL | $0.62 | 800,000 | $499,200 | 3,500,000 |
| 2025-10-02 23:56 | 2025-10-01 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $821.47 | 215,822 | $177,290,457 | 95,141,978 |
| 2025-10-02 23:55 | 2025-10-01 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $794.15 | 135,193 | $107,363,021 | 95,357,800 |
| 2025-10-02 23:51 | 2025-10-01 | MAIA | MAIA Biotechnology, Inc. | Smith Stan | Director | BUY | $1.30 | 19,230 | $24,999 | 1,324,289 |
| 2025-10-03 02:24 | 2025-10-01 | TERN | Terns Pharmaceuticals, Inc. | Kuriakose Emil | Officer | SELL | $7.85 | 944 | $7,407 | 51,520 |
| 2025-10-03 02:35 | 2025-10-02 | IONS | IONIS PHARMACEUTICALS INC | Baroldi Joseph | Officer | OPT+S | $68.01 | 15,000 | $1,020,210 | 31,926 |
| 2025-10-03 02:36 | 2025-10-01 | IONS | IONIS PHARMACEUTICALS INC | Swayze Eric | Officer | OPT+S | $66.16 | 27,114 | $1,793,743 | 37,302 |
| 2025-10-02 16:02 | 2025-10-01 | IMRX | Immuneering Corp | Morales Mallory | Officer | BUY | $6.39 | 300 | $1,917 | 27,533 |
| 2025-10-02 15:57 | 2025-10-01 | IMRX | Immuneering Corp | Neufeld Leah R | Officer | BUY | $6.38 | 800 | $5,103 | 23,344 |
| 2025-10-02 15:52 | 2025-10-01 | IMRX | Immuneering Corp | Bookman Michael | Officer | BUY | $6.83 | 1,020 | $6,966 | 4,870 |
| 2025-10-02 23:15 | 2025-09-30 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Klee Justin B. | Director, Officer | SELL | $14.38 | 29,975 | $430,954 | 3,325,301 |
| 2025-10-02 23:15 | 2025-09-30 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Mazzariello Gina | Officer | SELL | $14.58 | 8,828 | $128,669 | 148,141 |
| 2025-10-02 23:15 | 2025-09-30 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Cohen Joshua B | Director, Officer | SELL | $14.35 | 29,933 | $429,470 | 3,325,347 |
| 2025-10-03 02:18 | 2025-09-30 | ORIC | Oric Pharmaceuticals, Inc. | Chacko Jacob | Director, Officer | SELL | $12.04 | 87,539 | $1,053,558 | 568,880 |
| 2025-10-03 02:35 | 2025-10-02 | IONS | IONIS PHARMACEUTICALS INC | O'NEIL PATRICK R. | Officer | OPT+S | $67.69 | 64,664 | $4,377,054 | 57,130 |
| 2025-10-02 23:17 | 2025-09-30 | ANNX | Annexon, Inc. | Carson William H. | Director | BUY | $3.05 | 4,115 | $12,551 | 42,060 |
| 2025-10-02 23:02 | 2025-09-30 | APLS | Apellis Pharmaceuticals Inc. | Dunlop A. Sinclair | Director | SELL | $22.58 | 31,092 | $702,057 | 33,979 |
| 2025-10-03 03:51 | 2025-09-30 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $1.80 | 7,665 | $13,799 | 1,838,096 |
| 2025-10-02 23:03 | 2025-09-30 | AGIO | Agios Pharmaceuticals Inc. | Scadden David | Director | OPT+S | $40.00 | 200 | $8,000 | 17,603 |
| 2025-10-02 23:02 | 2025-10-01 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Khattar Jack A. | Director, Officer | OPT+S | $48.07 | 40,173 | $1,931,116 | 1,160,870 |
| 2025-10-02 23:15 | 2025-09-30 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Bedrosian Camille L | Officer | SELL | $14.58 | 12,039 | $175,518 | 182,336 |
| 2025-10-03 00:04 | 2025-10-01 | AMPH | Amphastar Pharmaceuticals Inc. | Petersen Floyd F. | Director | SELL | $27.20 | 500 | $13,602 | 76,031 |
| 2025-10-02 23:15 | 2025-09-30 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | FRATES JAMES M | Officer | SELL | $14.65 | 10,558 | $154,650 | 280,430 |
| 2025-10-02 23:47 | 2025-09-30 | KALA | KALA BIO, Inc. | BAKER BROS. ADVISORS LP | SELL | $1.45 | 730,408 | $1,056,754 | 425,006 | |
| 2025-10-02 23:30 | 2025-10-02 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $436.60 | 11,000 | $4,802,574 | 36,781 |
| 2025-10-02 23:30 | 2025-10-01 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $430.17 | 8,000 | $3,441,322 | 130 |
| 2025-10-03 02:36 | 2025-10-01 | IONS | IONIS PHARMACEUTICALS INC | WENDER JOSEPH H | Director | SELL | $65.50 | 16,800 | $1,100,385 | 92,035 |
| 2025-10-02 23:44 | 2025-09-30 | SAVA | FILANA THERAPEUTICS, INC. | Cook Robert Christopher | Officer | BUY | $2.91 | 13,725 | $39,940 | 13,725 |
| 2025-10-02 23:10 | 2025-09-30 | AIMD | Ainos Inc. | Taiwan Carbon Nano Technology Corp | 10% owner | SELL | $3.48 | 2,706 | $9,426 | 1,046,206 |
| 2025-10-01 23:00 | 2025-09-30 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $763.39 | 113,694 | $86,793,272 | 95,492,993 |
| 2025-10-01 23:30 | 2025-09-29 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | Officer | SELL | $5.39 | 9,366 | $50,516 | 350,763 |
| 2025-10-01 23:57 | 2025-09-29 | BCAX | Bicara Therapeutics Inc. | Meisner Lara | Officer | OPT+S | $14.75 | 33,807 | $498,653 | 0 |
| 2025-10-01 23:30 | 2025-09-29 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | Director, Officer | SELL | $5.31 | 44,274 | $234,882 | 1,190,067 |
| 2025-10-02 03:17 | 2025-09-29 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer | OPT+S | $85.05 | 27,588 | $2,346,255 | 61,734 |
| 2025-10-02 03:14 | 2025-09-29 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer | OPT+S | $83.07 | 4,000 | $332,288 | 48,034 |
| 2025-10-01 20:07 | 2025-09-30 | PEPG | PepGen Inc. | Oxford Science Enterprises plc | BUY | $3.20 | 200,000 | $640,000 | 4,955,388 | |
| 2025-10-01 15:59 | 2025-09-30 | IMRX | Immuneering Corp | Feinberg Peter | Director | BUY | $7.03 | 7,500 | $52,730 | 149,266 |
| 2025-10-01 23:44 | 2025-09-29 | KNSA | Kiniksa Pharmaceuticals International, plc | Tessari Eben | Officer | OPT+S | $38.33 | 42,000 | $1,609,860 | 34,552 |
| 2025-10-01 23:30 | 2025-09-29 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | Officer | SELL | $5.39 | 9,035 | $48,730 | 453,631 |
| 2025-10-01 23:46 | 2025-09-29 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Officer | OPT+S | $20.40 | 3,250 | $66,291 | 23,000 |
| 2025-10-02 00:22 | 2025-09-29 | MLTX | MoonLake Immunotherapeutics | Chen Bihua | SELL | $7.21 | 6,499,978 | $46,868,091 | 1,994,173 | |
| 2025-10-02 02:17 | 2025-10-01 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Director, Officer | OPT+S | $40.16 | 25,000 | $1,004,000 | 31,302 |
| 2025-10-01 23:55 | 2025-09-29 | IONS | IONIS PHARMACEUTICALS INC | O'NEIL PATRICK R. | Officer | OPT+S | $64.62 | 25,300 | $1,634,921 | 57,130 |
| 2025-10-02 01:04 | 2025-09-29 | SION | Sionna Therapeutics, Inc. | Booth Bruce | Director | SELL | $30.08 | 78,693 | $2,367,471 | 794,075 |
| 2025-10-01 23:55 | 2025-09-30 | IONS | IONIS PHARMACEUTICALS INC | Geary Richard S | Officer | OPT+S | $65.24 | 57,900 | $3,777,668 | 79,657 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.